Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
RedHill Biopharma ( (RDHL) ) has provided an update.
On December 15, 2025, RedHill Biopharma announced positive in vivo results for opaganib, showing its potential to reduce Chronic Lymphocytic Leukemia (CLL) cells by 50% when combined with venetoclax, a key CLL therapy. This development highlights opaganib’s potential as an add-on therapy to overcome venetoclax resistance, which is a significant therapeutic challenge in CLL treatment. The findings are part of ongoing research, including a Phase 2 study of opaganib with darolutamide in advanced prostate cancer, and may enhance RedHill’s position in the oncology market.
The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Underperform.
RedHill Biopharma’s overall stock score is primarily influenced by its challenging financial performance, characterized by significant losses and high leverage. The technical analysis suggests a bearish trend, further impacting the score. The absence of valuation metrics and earnings call data limits a comprehensive assessment, resulting in a low overall score.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company based in Tel Aviv, Israel. The company focuses on developing and commercializing innovative therapies for gastrointestinal diseases, oncology, and infectious diseases. Its product pipeline includes opaganib, a proprietary investigational drug with anticancer, anti-inflammatory, and antiviral activity, targeting multiple indications such as oncology, virology, and inflammation.
Average Trading Volume: 1,852,381
Technical Sentiment Signal: Sell
Current Market Cap: $5.47M
For an in-depth examination of RDHL stock, go to TipRanks’ Overview page.